Preparation method and application of injectable magnetothermal responsive thermosensitive hydrogel
By developing an injectable magnetothermal-responsive thermosensitive hydrogel, using iron tetraoxide nanoparticles and agarose to combine BMAP-27 peptides, the hydrogel state changes using external magnetic fields, achieving high efficiency for endometriosis Magnetothermal controlled release treatment solves the problem of insufficient application of trauma treatment of hydrogels in the prior art, and achieves effective inflammation suppression and pain relief.
Patent Information
- Application Number
- CN202410616762.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-05-17
AI Technical Summary
Existing treatment methods for endometriosis such as endocrine therapy and surgical treatment have problems that are traumatic and affect reproductive health, and have not yet been effectively explored in-depth treatment of non-neoplastic diseases such as endometriosis, especially It is the inadequate application of hydrogel systems in this field.
Develop an injectable magnetothermal-responsive thermosensitive hydrogel. By preparing iron tetraoxide nanoparticles and agarose hydrogel, combined with BMAP-27 polypeptide, the hydrogel state changes using external magnetic field to achieve local magnetothermal controlled release. Drugs to relieve inflammation and pain.
Local magnetothermal controlled release of iron trioxide and BMAP-27 polypeptide is achieved, effectively inhibiting the inflammatory environment of endometriosis tissues, relieving pain, and having good clinical application value and stability, simplifying the process and reducing costs.
Smart Images

Figure CN118557722B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of magnetic heat therapy combined with anti-inflammatory treatment of endometriosis, and in particular to a preparation method and application of an injectable magnetic heat responsive thermosensitive hydrogel. Background Art
[0002] At present, the conventional treatments for endometriosis are endocrine and surgical treatments. To prevent recurrence, surgical treatment is extremely invasive and requires the removal of normal tissue that is larger than the lesion range. It is also impossible to treat multiple diffuse lesions at the same time. Therefore, it will seriously affect the function of normal tissues, often leading to infertility and seriously affecting women's reproductive health. Long-term endocrine drug treatment will seriously affect the body's normal physiological functions and cause a series of adverse reactions and complications, including nausea, vomiting and breast malignancies.
[0003] Nanoparticle-mediated magnetic hyperthermia is a clinical intervention to treat tumor tissue by increasing tumor temperature. The rationale for using magnetic hyperthermia in cancer treatment has been well established in preclinical and clinical studies.
[0004] Hydrogels have shown good clinical application prospects in the field of nanobiotechnology. They are widely used in drug delivery because they can control drug release, reduce drug toxicity and side effects, and enhance tumor-killing effects in different ways.
[0005] Local injection of magnetic nanoparticle hydrogels into tumors has been shown to be a more effective drug delivery strategy, with advantages such as high enrichment efficiency, long retention time, and prevention of nanoparticle leakage. However, there has been no in-depth exploration of other non-tumor diseases, such as endometriosis. Therefore, it is imperative to develop a multifunctional hydrogel system with good biocompatibility and degradability, injectable and controllable release, and simultaneously achieve multiple combined treatments for endometriosis.
[0006] Studies have shown that ferroferric oxide nanoparticles have great application potential in the biomedical field due to their low cost, high biocompatibility, high magnetothermal properties and good stability. Their magnetothermal effect can cause cell death. Therefore, it is necessary to develop an injectable ferroferric oxide temperature-sensitive controlled-release agarose hydrogel system to fill the gap in the existing hydrogel system for endometriosis and solve the urgent problems in the clinical treatment of this disease. Summary of the invention
[0007] The present invention provides a preparation method and application of an injectable magnetothermal responsive thermosensitive hydrogel to fill the gap of the existing hydrogel system in endometriosis.
[0008] To achieve the above object, the present invention provides a method for preparing an injectable magnetothermal responsive thermosensitive hydrogel, comprising the following steps:
[0009] S1. Preparation of Fe3O4-PAA nanoparticles.
[0010] S2. 3.125 mg / mL agarose solution, 2 mg / mL BMAP-27 aqueous solution and 30 mg / mL ferrosoferric oxide nanoparticle aqueous solution were mixed in sequence at a volume ratio of 8:1:1, and left at room temperature for 3 minutes to form a magnetothermally responsive thermosensitive hydrogel.
[0011] Preferably, in step S1, the method for preparing ferroferric oxide nanoparticles Fe3O4-PAA comprises:
[0012] S1-1, dissolving ferric acetylacetonate in a mixed solution of ethylene glycol and diethylene glycol, and reacting for 30 minutes under magnetic stirring to obtain solution A;
[0013] S1-2, adding sodium acrylate to solution A, reacting at 80°C under magnetic stirring for 30 minutes to obtain solution B;
[0014] S1-3, add sodium acetate to solution B, and continue stirring at 80°C for 45 min;
[0015] S1-4, after the reaction in S1-3 is completed, the mixed solution is transferred to a stainless steel autoclave lined with Teflon, kept at 200°C for 24 hours, and the black product in the autoclave is taken out;
[0016] The black product was centrifuged at 14000 rpm for 10 min, and the precipitate was collected; after washing and drying, the precipitate was the ferroferric oxide nanoparticles Fe3O4-PAA.
[0017] Preferably, ferric acetylacetonate:ethylene glycol:diethylene glycol=1 g:30 mL:20 mL; sodium acrylate:ferric acetylacetonate:sodium acetate=1.5:1:2.
[0018] Preferably, in the magnetothermal responsive thermosensitive hydrogel prepared in step S2, the mass content of agarose is 0.25wt%; the content of ferrosoferric oxide nanoparticles is 3mg / mL, and the mass content of BMAP-27 is 0.2mg / mL.
[0019] Preferably, the ferrosoferric oxide nanoparticles are regular spherical structures with a diameter of 50 nm to 100 nm.
[0020] Since ferrosoferric oxide nanoparticles have good tissue penetration and efficient magnetothermal properties, under the action of an external magnetic field, ferrosoferric oxide can heat up to generate heat, causing the gel-state agarose hydrogel to dissolve into a sol state, thereby achieving controllable release of the BMAP-27 polypeptide, realizing local administration to the lesion site, improving the inflammatory environment around the ectopic uterine tissue and relieving pain.
[0021] The present invention has the following beneficial effects:
[0022] (1) It has good magnetic field responsiveness and can realize the transformation of the hydrogel from the gel state to the sol state under the action of the external sympathetic magnetic field, thereby realizing the local magnetothermal controlled release of ferroferric oxide and BMAP-27 peptide;
[0023] (2) BMAP-27 peptide has a good anti-inflammatory effect, which can inhibit the pro-inflammatory environment of endometriotic tissue and relieve the pain associated with endometriosis;
[0024] (3) The content of ferrosoferric oxide nanoparticles is 3 mg / mL, and the mass content of BMAP-27 polypeptide is 0.2 mg / mL. The ferrosoferric oxide nanoparticles with this content have the highest magnetothermal conversion efficiency within a certain concentration range, which is beneficial to improving the stability of the inductive magnetic field controlled release system and the ability to control the release of BMAP-27 polypeptide;
[0025] (4) It is responsive to the sympathetic magnetic field (405kHZ, 1.2kA / m), and simultaneously exerts the magnetic thermal treatment effect of the magnetic thermal material and the local anti-inflammatory effect of the BMAP-27 polypeptide, and has excellent clinical application value.
[0026] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The specification test results of the Fe3O4-PAA nanoparticles in Example 1 of the present invention; wherein (a) is a transmission electron microscope image of the Fe3O4-PAA nanoparticles; (b) is a lattice test image of the Fe3O4-PAA nanoparticles;
[0028] Figure 2 is the hydrated particle size of the Fe3O4-PAA nanoparticles in Example 1 of the present invention;
[0029] Figure 3 This is a schematic diagram of the magnetocaloric performance test results of ferroferric oxide (Fe3O4-PAA) nanoparticles at different concentrations in Example 1 of the present invention;
[0030] Figure 4This is a schematic diagram of the test results of the magnetic thermal stability of ferroferric oxide (Fe3O4-PAA) nanoparticles in Example 1 of the present invention;
[0031] Figure 5 Schematic diagram of the dynamic volume change rate of BMAP-27 / Fe3O4@Gel in Example 1 of the present invention; wherein (a) is the influence of the sympathetic magnetic field on the volume change of the hydrogel system measured by the ruler without ferroferric oxide nanoparticles; (b) is the influence of the sympathetic magnetic field on the volume change of the hydrogel system measured by the ruler with ferroferric oxide nanoparticles; (c) is a quantitative analysis diagram of the data obtained by the measurement of the ruler (three sets of parallel experiments);
[0032] Figure 6 This is a schematic diagram of the apoptosis results of endometriosis cells treated with BMAP-27 / Fe3O4@Gel magnetic heat / anti-inflammatory therapy in Example 1 of the present invention;
[0033] Figure 7 The figure shows the process of establishing the endometriosis model in SD rats and the schematic diagram of the changes in endometriotic tissue before and after treatment; (a) is the acquisition of endometrial tissue; (b) is the in situ suturing of the tissue to the right lower abdominal wall; (c) is the size and morphological appearance of the ectopic lesions 4 weeks after modeling; (d) is the size and morphological appearance of the ectopic lesions 10 days after treatment;
[0034] Figure 8 Schematic diagram of endometriosis tissues in different groups of rats after BMAP-27 / Fe3O4@Gel magnetic heat / anti-inflammatory synergistic treatment in Example 1 of the present invention. DETAILED DESCRIPTION
[0035] In order to make the purpose, technical scheme and advantages disclosed in the embodiments of the present invention clearer, the embodiments of the present invention are further described in detail in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the embodiments of the present invention and are not intended to limit the embodiments of the present invention. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application. Examples of the embodiments are shown in the accompanying drawings, where the same or similar reference numerals throughout represent the same or similar elements or elements with the same or similar functions.
[0036] It should be noted that the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, system, product or server that includes a series of steps or units is not necessarily limited to those steps or units explicitly listed, but may include other steps or units that are not explicitly listed or inherent to these processes, methods, products or devices.
[0037] Like reference numerals and letters denote similar items in the following drawings, and thus, once an item is defined in one drawing, further definition and explanation thereof is not required in subsequent drawings.
[0038] Embodiment 1
[0039] A method for preparing an injectable magnetothermal responsive thermosensitive hydrogel (BMAP-27 / Fe3O4@Gel), comprising the following steps:
[0040] S1. Preparation of Fe3O4-PAA nanoparticles
[0041] 1 g of ferric acetylacetonate was dissolved in a mixed solution of 30 mL of ethylene glycol and 20 mL of diethylene glycol, and the mixture was reacted at 80° C. and 800 rpm with magnetic stirring for 30 min to obtain solution A.
[0042] After the reaction, 1.5 g of sodium acrylate was added to solution A, and the mixture was reacted at 80° C. and 800 rpm for 30 min under magnetic stirring to obtain solution B. 2 g of sodium acetate was added to solution B, and stirring was continued at 80° C. and 800 rpm for 45 min.
[0043] After the reaction is completed, the mixed solution is transferred to a stainless steel autoclave lined with Teflon, kept at 200°C for 24 hours, and the black product in the autoclave is taken out. The product is centrifuged at 14000rpm for 10 minutes, and the precipitate is collected. The precipitate is washed with anhydrous ethanol and pure water for 3 times each, and the final product is ferrosoferric oxide nanoparticles (Fe3O4-PAA). Fe3O4-PAA can be stored in anhydrous ethanol at 4°C.
[0044] S2. Disperse 30 mg of ferrosoferric oxide nanoparticles (Fe3O4-PAA) in 1 mL of water, and ultrasonicate for 30 s at a nominal power of 1200 W to obtain a 30 mg / mL Fe3O4-PAA aqueous solution.
[0045] 2 mg of BMAP-27 polypeptide was dispersed in 1 mL of water and vortexed for 10 s to obtain a 2 mg / mL BMAP-27 aqueous solution.
[0046] Dissolve 62.5 mg of agarose in 20 mL of 1×TAE buffer and heat in a water bath to 100°C to fully dissolve. Use the solution when the temperature drops to 45°C while it is still in liquid form.
[0047] S3. Mix the agarose solution, BMAP-27 aqueous solution, and Fe3O4-PAA aqueous solution in a volume ratio of 8:1:1, and leave at room temperature for 3 minutes to form a gel BMAP-27 / Fe3O4@Gel.
[0048] Experimental Testing
[0049] (1) Take an appropriate amount of Fe3O4-PAA and add it dropwise onto a double copper mesh after ultrasonic treatment, dry it to prepare a transmission electron microscopy sample, and observe it with a transmission electron microscope. Figure 1 shown.
[0050] according to Figure 1 As shown in (a), Fe3O4-PAA has a regular spherical structure with a particle size of about 50-100nm and is relatively dispersed.
[0051] Figure 1 (b) shows the lattice structure of Fe3O4-PAA, whose lattice spacing is 0.29644nm, which is consistent with the 220 interface lattice spacing.
[0052] (2) Fe3O4-PAA was tested by dynamic light scattering analyzer (DLS). An appropriate amount of Fe3O4-PAA-ethanol solution was taken, centrifuged to remove the supernatant, and then resuspended with 1 mL of pure water. The hydrated particle size of Fe3O4-PAA was measured by dynamic light scattering analyzer (DLS). Figure 2 shown.
[0053] The hydrated particle size of Fe3O4-PAA is about 108.4nm.
[0054] (3) Prepare 0, 500, 1000, 2000, and 3000 μg / mL Fe3O4-PAA solutions respectively, apply an external sympathetic magnetic field (405 kHZ, 1.2 kA / m) for 10 min, use an infrared temperature camera to record the temperature change of the solution per second, and draw a temperature change curve, such as Figure 3 The results show that as the concentration of Fe3O4-PAA solution increases, the temperature will also increase.
[0055] (4) Prepare 3000 μg / mL Fe3O4-PAA solution and apply four periodic on / off sympathetic magnetic fields. Figure 4 It can be seen that during the entire cycle, the Fe3O4-PAA solution subjected to the sympathetic magnetic field can be quickly heated to a maximum of 71°C, and can gradually cool to the initial temperature after the sympathetic magnetic field is turned off, indicating that Fe3O4-PAA has stable magnetothermal conversion performance.
[0056] (5) Figure 5 As shown, it is a schematic diagram of the dynamic volume change rate of BMAP-27 / Fe3O4@Gel according to Example 1 of the present invention. Figure 5 (a) and (b) show the effect of the sympathetic magnetic field on the volume change of the hydrogel system with and without ferroferric oxide nanoparticles. Figure 5 (c) is a quantitative analysis chart of the data obtained from the measurement of the graph ruler (three sets of parallel experiments).
[0057] Depend on Figure 5 It can be seen that BMAP-27 / Fe3O4@Gels has a higher dynamic volume change rate under the action of the sympathetic magnetic field, indicating that it is easier to release drugs in the system.
[0058] (6) Figure 6 This is a schematic diagram of the results of BMAP-27 / Fe3O4@Gel inducing apoptosis of endometriosis cells in Example 1 of the present invention.
[0059] The dyes used in the apoptosis experiment are Annexin-V FITC and 7-AAD. Q1 represents Annexin-V FITC- / 7-AAD+, indicating cell death; Q2 represents Annexin-V FITC+ / 7-AAD+, indicating late apoptosis; Q3 represents Annexin-V FITC+ / 7-AAD-, indicating early apoptosis; Q4 represents Annexin-V FITC- / 7-AAD-, indicating normal cells.
[0060] The experiment was divided into blank control group (NC), sympathetic magnetic field treatment group, BMAP-27 / Fe3O4@Gel treatment group, Fe3O4@Gel+sympathetic magnetic field treatment group, and BMAP-27 / Fe3O4@Gel+sympathetic magnetic field treatment group. Figure 6 The figure shows the cell apoptosis in different groups. From left to right, it can be seen that the proportion of apoptotic cells gradually increases, and the cell apoptosis rate of the BMAP-27 / Fe3O4@Gel+AMF group is as high as 69.8%, indicating that BMAP-27 / Fe3O4@Gel has a strong ability to promote cell apoptosis.
[0061] (7) Figure 7 Flow chart for establishing the endometriosis model in SD rats using autologous endometrial transplantation. Figure 7 As shown in the figure, an endometriosis model was successfully established, where (a) is the acquisition of endometrial tissue; (b) is the in situ suturing of the tissue to the right lower abdominal wall; (c) is the size and morphological appearance of the ectopic lesions 4 weeks after modeling; (d) is the size and morphological appearance of the ectopic lesions 10 days after treatment. Before and after treatment, the volume of the ectopic endometrial tissue decreased, indicating that BMAP-27 / Fe3O4@Gel has a good therapeutic effect.
[0062] (8) Figure 8Schematic diagram of ectopic tissues in different groups of endometriosis rats after treatment. The groups include: blank control group (NC) without treatment, sympathetic magnetic field treatment group, BMAP-27 / Fe3O4@Gel treatment group, Fe3O4@Gel+sympathetic magnetic field treatment group, and BMAP-27 / Fe3O4@Gel+sympathetic magnetic field treatment group.
[0063] like Figure 8 As shown in the figure, after treatment, the volume of ectopic endometrial tissue in different groups gradually decreased, and the BMAP-27 / Fe3O4@Gel+AMF group had the best therapeutic effect, indicating that BMAP-27 / Fe3O4@Gel has a good therapeutic effect.
[0064] Therefore, the preparation method and application of the injectable magnetothermal responsive thermosensitive hydrogel of the present invention have excellent magnetothermal conversion ability and can effectively control the release of polypeptides, thereby promoting the apoptosis of the ectopic tissue and inhibiting the pro-inflammatory environment, and can be applied to the field of efficient synergistic treatment of endometriosis; and the process of the present invention is simple, the cost of raw materials is low, and it is easy to mass produce.
Claims
1. A method for preparing an injectable magnetothermal responsive thermosensitive hydrogel, characterized in that: The steps include: S1. Preparation of ferroferric oxide nanoparticles Fe3O4-PAA; S2. 3.125 mg / mL agarose solution, 2 mg / mL BMAP-27 aqueous solution and 30 mg / mL ferrosoferric oxide nanoparticles Fe3O4-PAA aqueous solution were mixed in sequence at a volume ratio of 8:1:1, and placed at room temperature for 3 minutes to form a magnetothermal responsive thermosensitive hydrogel.
2. The method for preparing an injectable magnetothermal responsive thermosensitive hydrogel according to claim 1, characterized in that: In step S1, the preparation method of ferroferric oxide nanoparticles Fe3O4-PAA includes: S1-1, dissolving ferric acetylacetonate in a mixed solution of ethylene glycol and diethylene glycol, and reacting for 30 minutes under magnetic stirring to obtain solution A; S1-2, adding sodium acrylate to solution A, reacting at 80°C under magnetic stirring for 30 minutes to obtain solution B; S1-3, add sodium acetate to solution B, and continue stirring at 80°C for 45 min; S1-4, after the reaction in S1-3 is completed, the mixed solution is transferred to a stainless steel autoclave lined with Teflon, kept at 200°C for 24 hours, and the black product in the autoclave is taken out; The black product was centrifuged at 14000 rpm for 10 min, and the precipitate was collected; after washing and drying, the precipitate was the ferroferric oxide nanoparticles Fe3O4-PAA.
3. The method for preparing an injectable magnetothermal responsive thermosensitive hydrogel according to claim 2, characterized in that: Ferrous acetylacetonate: ethylene glycol: diethylene glycol = 1 g: 30 mL: 20 mL; mass ratio of sodium acrylate: ferrous acetylacetonate: sodium acetate = 1.5: 1:
2.
4. The method for preparing an injectable magnetothermal responsive thermosensitive hydrogel according to claim 1, characterized in that: In the magnetothermal responsive thermosensitive hydrogel prepared in step S2, the mass content of agarose is 0.25wt%; the mass content of ferrosoferric oxide nanoparticles is 3mg / mL, and the mass content of BMAP-27 is 0.2mg / mL.
5. The method for preparing an injectable magnetothermal responsive thermosensitive hydrogel according to claim 1, characterized in that: The ferrosoferric oxide nanoparticles are regular spherical structures with a diameter of 50nm-100nm.
6. An injectable magnetothermal responsive thermosensitive hydrogel prepared by the method for preparing an injectable magnetothermal responsive thermosensitive hydrogel as described in any one of claims 1 to 5.
7. Use of the injectable magnetothermal responsive thermosensitive hydrogel as claimed in claim 6 in the preparation of a drug for inducing apoptosis of endometriosis cells, inhibiting the pro-inflammatory environment of endometriosis tissue, and relieving pain associated with endometriosis.
8. Use of the injectable magnetothermal responsive thermosensitive hydrogel as claimed in claim 6 in the preparation of a drug for use in combination with a sympathetic magnetic field, characterized in that: Under the action of external heat generated by the sympathetic magnetic field, the temperature of the ferroferric oxide nanoparticles rises, causing the magnetothermal responsive thermosensitive hydrogel to dissolve into a sol state, thereby achieving the controllable release of the BMAP-27 polypeptide and ferroferric oxide nanoparticles.
